应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
CTOR CITIUS ONCOLOGY INC
盘前交易 02-11 09:24:45 EST
1.13
+0.02
+1.80%
盘前
1.17
+0.04
+3.54%
09:10 EST
最高
1.16
最低
1.08
成交量
12.05万
今开
1.09
昨收
1.11
日振幅
7.02%
总市值
9,975万
流通市值
1,392万
总股本
8,828万
成交额
13.56万
换手率
0.98%
流通股本
1,232万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
Citius Oncology与Uniphar达成独家协议 将淋巴瘤药物Lymphir™分销版图扩展至欧盟
美股速递 · 21:03
Citius Oncology与Uniphar达成独家协议 将淋巴瘤药物Lymphir™分销版图扩展至欧盟
Citius Oncology, Inc.盘中异动 早盘股价大跌5.42%
市场透视 · 01-27
Citius Oncology, Inc.盘中异动 早盘股价大跌5.42%
Citius Oncology, Inc.盘中异动 大幅拉升5.61%
市场透视 · 01-13
Citius Oncology, Inc.盘中异动 大幅拉升5.61%
Citius Oncology, Inc.盘中异动 早盘急速下挫6.96%
市场透视 · 01-06
Citius Oncology, Inc.盘中异动 早盘急速下挫6.96%
Citius Oncology, Inc.盘中异动 早盘大幅下挫5.31%报1.07美元
市场透视 · 2025-12-29
Citius Oncology, Inc.盘中异动 早盘大幅下挫5.31%报1.07美元
Citius Oncology完成1800万美元的同时注册直接发行和私募配售,价格符合纳斯达克规则
美股速递 · 2025-12-11
Citius Oncology完成1800万美元的同时注册直接发行和私募配售,价格符合纳斯达克规则
Citius Oncology Inc - 直接发行以每股1.09美元购买1,284,404股普通股
美股速递 · 2025-12-09
Citius Oncology Inc - 直接发行以每股1.09美元购买1,284,404股普通股
Citius Oncology 宣布以市场定价进行1800万美元的注册直销及私人投资
美股速递 · 2025-12-09
Citius Oncology 宣布以市场定价进行1800万美元的注册直销及私人投资
Citius Oncology通过与Er-Kim的独家协议扩展Lymphir™在土耳其和中东国家的分销
美股速递 · 2025-12-04
Citius Oncology通过与Er-Kim的独家协议扩展Lymphir™在土耳其和中东国家的分销
Citius Oncology 宣布 Lymphir™ 上市,作为切肤性 T 细胞淋巴瘤的新型癌症免疫疗法
美股速递 · 2025-12-02
Citius Oncology 宣布 Lymphir™ 上市,作为切肤性 T 细胞淋巴瘤的新型癌症免疫疗法
Citius Oncology, Inc.盘中异动 急速上涨5.62%
市场透视 · 2025-11-21
Citius Oncology, Inc.盘中异动 急速上涨5.62%
Citius Oncology与麦克森签署美国分销协议以支持Lymphir™商业推广
美股速递 · 2025-10-20
Citius Oncology与麦克森签署美国分销协议以支持Lymphir™商业推广
Citius Oncology与Eversana签订独家商业化协议,助力计划于2025年第四季度推出Lymphir™
美股速递 · 2025-10-16
Citius Oncology与Eversana签订独家商业化协议,助力计划于2025年第四季度推出Lymphir™
Citius Oncology宣布完成900万美元注册直接发行和同步私募配售定价
美股速递 · 2025-09-09
Citius Oncology宣布完成900万美元注册直接发行和同步私募配售定价
Citius Oncology, Inc.盘中异动 股价大跌8.51%报0.860美元
市场透视 · 2025-03-10
Citius Oncology, Inc.盘中异动 股价大跌8.51%报0.860美元
Citius Oncology, Inc.盘中异动 快速拉升6.42%
市场透视 · 2025-03-06
Citius Oncology, Inc.盘中异动 快速拉升6.42%
Citius Oncology, Inc.盘中异动 早盘股价大涨6.73%
市场透视 · 2025-03-04
Citius Oncology, Inc.盘中异动 早盘股价大涨6.73%
Citius Oncology, Inc.盘中异动 早盘大幅跳水5.04%
市场透视 · 2025-03-04
Citius Oncology, Inc.盘中异动 早盘大幅跳水5.04%
Citius Oncology, Inc.盘中异动 股价大跌6.72%
市场透视 · 2025-03-01
Citius Oncology, Inc.盘中异动 股价大跌6.72%
Citius Oncology, Inc.盘中异动 早盘快速下挫5.51%报1.12美元
市场透视 · 2025-02-27
Citius Oncology, Inc.盘中异动 早盘快速下挫5.51%报1.12美元
加载更多
公司概况
公司名称:
CITIUS ONCOLOGY INC
所属市场:
NASDAQ
上市日期:
--
主营业务:
Citius Oncology, Inc.(前身为TenX Keane Acquisition)于2021年3月1日在开曼群岛注册成立,并于2024年8月5日作为特拉华州公司迁移并归化。Citius Oncology将作为一个平台,开发和商业化新型靶向肿瘤疗法。2024年8月,其主要资产LYMPHIR获得FDA批准,用于治疗至少接受过一次全身治疗的复发或难治性CTCL成人患者。
发行价格:
--
{"stockData":{"symbol":"CTOR","market":"US","secType":"STK","nameCN":"CITIUS ONCOLOGY INC","latestPrice":1.13,"timestamp":1770757200000,"preClose":1.11,"halted":0,"volume":120491,"hourTrading":{"tag":"盘前","latestPrice":1.17,"preClose":1.13,"latestTime":"09:10 EST","volume":10616,"amount":12315.233054400001,"timestamp":1770819049041,"change":0.04,"changeRate":0.035398,"amplitude":0.030619},"delay":0,"changeRate":0.018018018018017834,"floatShares":12321000,"shares":88275200,"eps":-0.337956,"marketStatus":"盘前交易","change":0.02,"latestTime":"02-11 09:24:45 EST","open":1.09,"high":1.158,"low":1.0801,"amount":135648.4304252,"amplitude":0.07018,"askPrice":1.18,"askSize":100,"bidPrice":1.1,"bidSize":2418,"shortable":3,"etf":0,"ttmEps":-0.337956,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1770820200000},"marketStatusCode":1,"adr":0,"exchange":"NASDAQ","adjPreClose":1.13,"preHourTrading":{"tag":"盘前","latestPrice":1.17,"preClose":1.13,"latestTime":"09:10 EST","volume":10616,"amount":12315.233054400001,"timestamp":1770819049041,"change":0.04,"changeRate":0.035398,"amplitude":0.030619},"postHourTrading":{"tag":"盘后","latestPrice":1.16,"preClose":1.13,"latestTime":"19:26 EST","volume":5942,"amount":6892.0449,"timestamp":1770769614518,"change":0.03,"changeRate":0.026549,"amplitude":0.026549},"volumeRatio":0.8311099775690066},"requestUrl":"/m/hq/s/CTOR","defaultTab":"news","newsList":[{"id":"1122767016","title":"Citius Oncology与Uniphar达成独家协议 将淋巴瘤药物Lymphir™分销版图扩展至欧盟","url":"https://stock-news.laohu8.com/highlight/detail?id=1122767016","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1122767016?lang=zh_cn&edition=full","pubTime":"2026-02-11 21:03","pubTimestamp":1770815018,"startTime":"0","endTime":"0","summary":"生物制药企业Citius Oncology宣布与欧洲领先医疗产品服务商Uniphar签署独家分销协议,正式将其创新淋巴瘤疗法Lymphir™的商业化版图拓展至欧盟市场。\n此次合作将依托Uniphar在欧洲建立的成熟分销网络,加速Lymphir™在欧盟地区的准入进程。该协议不仅强化了Citius Oncology的全球化战略布局,也为欧洲患者提供了更前沿的治疗选择。\nLymphir™作为针对特定淋巴瘤亚型的靶向疗法,此前已在部分国际市场展现出临床潜力。通过本次渠道拓展,Citius Oncology有望进一步提升其在肿瘤治疗领域的国际影响力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTXR","CTOR","BK4007","BK4139"],"gpt_icon":0},{"id":"2606759209","title":"Citius Oncology, Inc.盘中异动 早盘股价大跌5.42%","url":"https://stock-news.laohu8.com/highlight/detail?id=2606759209","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606759209?lang=zh_cn&edition=full","pubTime":"2026-01-27 22:33","pubTimestamp":1769524383,"startTime":"0","endTime":"0","summary":"北京时间2026年01月27日22时33分,Citius Oncology, Inc.股票出现异动,股价快速下挫5.42%。Citius Oncology, Inc.股票所在的制药行业中,整体涨幅为0.50%。其相关个股中,苏轩堂、Flora Growth Corp.、Apimeds Pharmaceuticals Us, Inc.涨幅较大,苏轩堂、Akanda Corp.、Flora Growth Corp.较为活跃,换手率分别为28.60%、5.54%、4.19%,振幅较大的相关个股有Flora Growth Corp.、Akanda Corp.、苏轩堂,振幅分别为17.09%、8.40%、8.39%。Citius Oncology, Inc.公司简介:Citius Oncology Inc是一家专注于开发和商业化靶向肿瘤疗法的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026012722330397a3a35c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026012722330397a3a35c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4183","CTOR","FLGC","ZSTK","BK4539","BK4139"],"gpt_icon":0},{"id":"2603769320","title":"Citius Oncology, Inc.盘中异动 大幅拉升5.61%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603769320","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603769320?lang=zh_cn&edition=full","pubTime":"2026-01-13 22:42","pubTimestamp":1768315358,"startTime":"0","endTime":"0","summary":"北京时间2026年01月13日22时42分,Citius Oncology, Inc.股票出现波动,股价急速上涨5.61%。Citius Oncology, Inc.股票所在的制药行业中,整体跌幅为0.43%。其相关个股中,Im Cannabis Corp.、Biofrontera Inc.、Citius Oncology, Inc.涨幅较大,Akanda Corp.、Gelteq Limited、苏轩堂较为活跃,换手率分别为14.79%、5.41%、4.31%,振幅较大的相关个股有脑再生科技、大自然药业、Biofrontera Inc.,振幅分别为16.55%、11.06%、10.04%。Citius Oncology, Inc.公司简介:Citius Oncology Inc是一家专注于开发和商业化靶向肿瘤疗法的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026011322423897a1a7b8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026011322423897a1a7b8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CTOR","BK4139"],"gpt_icon":0},{"id":"2601842432","title":"Citius Oncology, Inc.盘中异动 早盘急速下挫6.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601842432","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601842432?lang=zh_cn&edition=full","pubTime":"2026-01-06 22:32","pubTimestamp":1767709948,"startTime":"0","endTime":"0","summary":"北京时间2026年01月06日22时32分,Citius Oncology, Inc.股票出现异动,股价急速跳水6.96%。Citius Oncology, Inc.股票所在的制药行业中,整体涨幅为0.33%。其相关个股中,Caring Brands, Inc.、Gelteq Limited、脑再生科技涨幅较大,Akanda Corp.、Redhill Biopharma Ltd、Cbdmd, Inc.较为活跃,换手率分别为14.13%、3.33%、0.81%,振幅较大的相关个股有Caring Brands, Inc.、脑再生科技、Akanda Corp.,振幅分别为8.86%、6.33%、5.22%。Citius Oncology, Inc.公司简介:Citius Oncology Inc是一家专注于开发和商业化靶向肿瘤疗法的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260106223228953c16f3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260106223228953c16f3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","CTOR"],"gpt_icon":0},{"id":"2595500753","title":"Citius Oncology, Inc.盘中异动 早盘大幅下挫5.31%报1.07美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2595500753","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595500753?lang=zh_cn&edition=full","pubTime":"2025-12-29 22:48","pubTimestamp":1767019725,"startTime":"0","endTime":"0","summary":"北京时间2025年12月29日22时48分,Citius Oncology, Inc.股票出现波动,股价大幅跳水5.31%。Citius Oncology, Inc.股票所在的制药行业中,整体涨幅为0.09%。其相关个股中,Caring Brands, Inc.、Akanda Corp.、脑再生科技涨幅较大,Akanda Corp.、大自然药业、Cbdmd, Inc.较为活跃,换手率分别为117.47%、6.59%、5.20%,振幅较大的相关个股有Caring Brands, Inc.、脑再生科技、Cbdmd, Inc.,振幅分别为31.25%、18.85%、11.78%。Citius Oncology, Inc.公司简介:Citius Oncology Inc 是一家专业制药公司,致力于开发和商业化针对未满足需求的重症监护产品,专注于肿瘤产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251229224845a4868ab8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251229224845a4868ab8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4183","CABR","CTOR"],"gpt_icon":0},{"id":"1194721703","title":"Citius Oncology完成1800万美元的同时注册直接发行和私募配售,价格符合纳斯达克规则","url":"https://stock-news.laohu8.com/highlight/detail?id=1194721703","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1194721703?lang=zh_cn&edition=full","pubTime":"2025-12-11 05:31","pubTimestamp":1765402278,"startTime":"0","endTime":"0","summary":"Citius Oncology完成1800万美元的同时注册直接发行和私募配售,价格符合纳斯达克规则","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTOR","BK4139"],"gpt_icon":0},{"id":"1186772713","title":"Citius Oncology Inc - 直接发行以每股1.09美元购买1,284,404股普通股","url":"https://stock-news.laohu8.com/highlight/detail?id=1186772713","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1186772713?lang=zh_cn&edition=full","pubTime":"2025-12-09 21:33","pubTimestamp":1765287209,"startTime":"0","endTime":"0","summary":"Citius Oncology Inc - 直接发行以每股1.09美元购买1,284,404股普通股","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTXR","BK4007","CTOR","BK4139"],"gpt_icon":0},{"id":"1111513577","title":"Citius Oncology 宣布以市场定价进行1800万美元的注册直销及私人投资","url":"https://stock-news.laohu8.com/highlight/detail?id=1111513577","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111513577?lang=zh_cn&edition=full","pubTime":"2025-12-09 21:31","pubTimestamp":1765287103,"startTime":"0","endTime":"0","summary":"Citius Oncology 宣布以市场定价进行1800万美元的注册直销及私人投资","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","CTXR","CTOR"],"gpt_icon":0},{"id":"1178681935","title":"Citius Oncology通过与Er-Kim的独家协议扩展Lymphir™在土耳其和中东国家的分销","url":"https://stock-news.laohu8.com/highlight/detail?id=1178681935","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1178681935?lang=zh_cn&edition=full","pubTime":"2025-12-04 21:37","pubTimestamp":1764855430,"startTime":"0","endTime":"0","summary":"Citius Oncology通过与Er-Kim的独家协议扩展Lymphir™在土耳其和中东国家的分销","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CTXR","CTOR","BK4007"],"gpt_icon":0},{"id":"1108685707","title":"Citius Oncology 宣布 Lymphir™ 上市,作为切肤性 T 细胞淋巴瘤的新型癌症免疫疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=1108685707","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1108685707?lang=zh_cn&edition=full","pubTime":"2025-12-02 01:01","pubTimestamp":1764608490,"startTime":"0","endTime":"0","summary":"Citius Oncology 宣布在美国商业化推出 Lymphir™,这是一种针对切肤性 T 细胞淋巴瘤的新型癌症免疫疗法。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CTOR","CTXR","BK4007"],"gpt_icon":0},{"id":"2585127830","title":"Citius Oncology, Inc.盘中异动 急速上涨5.62%","url":"https://stock-news.laohu8.com/highlight/detail?id=2585127830","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585127830?lang=zh_cn&edition=full","pubTime":"2025-11-21 22:30","pubTimestamp":1763735424,"startTime":"0","endTime":"0","summary":"北京时间2025年11月21日22时30分,Citius Oncology, Inc.股票出现波动,股价急速上涨5.62%。Citius Oncology, Inc.股票所在的制药行业中,整体涨幅为0.00%。其相关个股中,Shuttle Pharmaceuticals Holdings, Inc.、Scilex Holding Company C/Wts 10/11/2027 、Citius Oncology, Inc.涨幅较大,Shuttle Pharmaceuticals Holdings, Inc.、Inmed Pharmaceuticals Inc.、Citius Oncology, Inc.较为活跃,换手率分别为170.12%、3.94%、1.49%,振幅较大的相关个股有Citius Oncology, Inc.、Scynexis, Inc.、Inmed Pharmaceuticals Inc.,振幅分别为4.42%、2.49%、2.36%。Citius Oncology, Inc.公司简介:Citius Oncology Inc 是一家专业制药公司,致力于开发和商业化针对未满足需求的重症监护产品,专注于肿瘤产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202511212230259777da73&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202511212230259777da73&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","CTOR"],"gpt_icon":0},{"id":"1149323781","title":"Citius Oncology与麦克森签署美国分销协议以支持Lymphir™商业推广","url":"https://stock-news.laohu8.com/highlight/detail?id=1149323781","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1149323781?lang=zh_cn&edition=full","pubTime":"2025-10-20 20:37","pubTimestamp":1760963831,"startTime":"0","endTime":"0","summary":"Citius Oncology与麦克森签署美国分销协议以支持Lymphir™商业推广","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTOR","LU2089984988.USD","LU0742534661.SGD","BK4175","LU0251142724.SGD","LU0203347892.USD","LU1366192091.USD","LU1430594728.SGD","LU2468319806.SGD","MCK","LU1814569148.SGD","BK4588","LU0965509101.SGD","LU0868494708.USD","LU0203345920.USD","BK4007","LU0048573561.USD","LU0942090050.USD","LU2112291526.USD","LU1037948897.HKD","LU1057294990.SGD","LU1585245621.USD","LU1934455863.HKD","CTXR","LU1506573853.SGD","LU0965508806.USD","LU1934455194.USD","LU0314106906.USD","LU1037948541.HKD","LU1983260115.SGD","LU1934455277.USD","LU0861579265.USD","LU0432979614.USD","LU0868494617.USD","LU0251131958.USD","LU0122379950.USD","LU0965509283.SGD","LU0965509010.AUD","BK4585","LU1061106388.HKD","BK4139","LU2324357040.USD","LU1023059063.AUD","BK4533"],"gpt_icon":0},{"id":"1125386068","title":"Citius Oncology与Eversana签订独家商业化协议,助力计划于2025年第四季度推出Lymphir™","url":"https://stock-news.laohu8.com/highlight/detail?id=1125386068","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1125386068?lang=zh_cn&edition=full","pubTime":"2025-10-16 20:48","pubTimestamp":1760618892,"startTime":"0","endTime":"0","summary":"Citius Oncology与Eversana签订独家商业化协议,助力计划于2025年第四季度推出Lymphir™","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","CTXR","CTOR"],"gpt_icon":0},{"id":"1198374736","title":"Citius Oncology宣布完成900万美元注册直接发行和同步私募配售定价","url":"https://stock-news.laohu8.com/highlight/detail?id=1198374736","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1198374736?lang=zh_cn&edition=full","pubTime":"2025-09-09 20:31","pubTimestamp":1757421080,"startTime":"0","endTime":"0","summary":"Citius Oncology宣布完成总额900万美元的注册直接发行和同步私募配售的定价工作。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTXR","BK4139","CTOR","BK4007"],"gpt_icon":0},{"id":"2518273720","title":"Citius Oncology, Inc.盘中异动 股价大跌8.51%报0.860美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518273720","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518273720?lang=zh_cn&edition=full","pubTime":"2025-03-10 22:19","pubTimestamp":1741616395,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日22时19分,Citius Oncology, Inc.股票出现异动,股价大幅跳水8.51%。截至发稿,该股报0.860美元/股,成交量1.9481万股,换手率0.03%,振幅3.23%。Citius Oncology, Inc.股票所在的制药行业中,整体跌幅为1.96%。Citius Oncology, Inc.公司简介:Citius Oncology Inc 是一家专业制药公司,致力于针对肿瘤产品未满足需求的重症护理产品的开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031022195598a2a913&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031022195598a2a913&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CTOR","BK4139"],"gpt_icon":0},{"id":"2517803941","title":"Citius Oncology, Inc.盘中异动 快速拉升6.42%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517803941","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517803941?lang=zh_cn&edition=full","pubTime":"2025-03-06 00:18","pubTimestamp":1741191502,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日00时18分,Citius Oncology, Inc.股票出现异动,股价快速上涨6.42%。Citius Oncology, Inc.股票所在的制药行业中,整体涨幅为0.30%。其相关个股中,Organogenesis Holdings Inc.、坎伯兰药业、Quantum Biopharma Ltd.涨幅较大,Painreform Ltd.、Petros Pharmaceuticals, Inc.、Quantum Biopharma Ltd.较为活跃,换手率分别为16.67%、10.66%、5.48%,振幅较大的相关个股有坎伯兰药业、Alpha Teknova, Inc.、Medicus Pharma Ltd.,振幅分别为27.93%、16.89%、14.66%。Citius Oncology, Inc.公司简介:Citius Oncology Inc 是一家专业制药公司,致力于针对肿瘤产品未满足需求的重症护理产品的开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306001822989d5f04&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306001822989d5f04&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","CTOR"],"gpt_icon":0},{"id":"2516082026","title":"Citius Oncology, Inc.盘中异动 早盘股价大涨6.73%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516082026","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516082026?lang=zh_cn&edition=full","pubTime":"2025-03-04 23:09","pubTimestamp":1741100966,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日23时09分,Citius Oncology, Inc.股票出现异动,股价快速拉升6.73%。Citius Oncology, Inc.股票所在的制药行业中,整体跌幅为0.13%。其相关个股中,Evoke Pharma, Inc.、Esperion Therapeutics, Inc.、Citius Oncology, Inc.涨幅较大,大自然药业、Emergent Biosolutions Inc.、Petros Pharmaceuticals, Inc.较为活跃,换手率分别为4.87%、4.06%、2.73%,振幅较大的相关个股有Therapeuticsmd, Inc.、Evoke Pharma, Inc.、Emergent Biosolutions Inc.,振幅分别为18.05%、15.18%、13.76%。Citius Oncology, Inc.公司简介:Citius Oncology Inc 是一家专业制药公司,致力于针对肿瘤产品未满足需求的重症护理产品的开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304230926989bb701&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304230926989bb701&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CTOR","BK4139"],"gpt_icon":0},{"id":"2516713658","title":"Citius Oncology, Inc.盘中异动 早盘大幅跳水5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516713658","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516713658?lang=zh_cn&edition=full","pubTime":"2025-03-04 00:01","pubTimestamp":1741017684,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日00时01分,Citius Oncology, Inc.股票出现波动,股价急速跳水5.04%。Citius Oncology, Inc.股票所在的制药行业中,整体涨幅为0.59%。其相关个股中,坎伯兰药业、Kiniksa Pharmaceuticals, Ltd.、Intercure Ltd.涨幅较大,Petros Pharmaceuticals, Inc.、苏轩堂、大自然药业较为活跃,换手率分别为17.43%、8.59%、6.87%,振幅较大的相关个股有Sunshine Biopharma Inc C/Wts 、Cyclo Therapeutics Inc C/Wts 11/12/2025、坎伯兰药业,振幅分别为35.16%、18.12%、17.49%。Citius Oncology, Inc.公司简介:Citius Oncology Inc 是一家专业制药公司,致力于针对肿瘤产品未满足需求的重症护理产品的开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304000124abe65102&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304000124abe65102&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","CTOR"],"gpt_icon":0},{"id":"2516379277","title":"Citius Oncology, Inc.盘中异动 股价大跌6.72%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516379277","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516379277?lang=zh_cn&edition=full","pubTime":"2025-03-01 00:19","pubTimestamp":1740759591,"startTime":"0","endTime":"0","summary":"北京时间2025年03月01日00时19分,Citius Oncology, Inc.股票出现异动,股价大幅下挫6.72%。Citius Oncology, Inc.股票所在的制药行业中,整体跌幅为0.24%。其相关个股中,Organogenesis Holdings Inc.、百利高、Sunshine Biopharma Inc C/Wts 涨幅较大,Organogenesis Holdings Inc.、苏轩堂、Petros Pharmaceuticals, Inc.较为活跃,换手率分别为32.15%、11.78%、8.21%,振幅较大的相关个股有Organogenesis Holdings Inc.、Sunshine Biopharma Inc C/Wts 、苏轩堂,振幅分别为57.65%、44.90%、18.00%。Citius Oncology, Inc.公司简介:Citius Oncology Inc 是一家专业制药公司,致力于针对肿瘤产品未满足需求的重症护理产品的开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250301001951abe1042b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250301001951abe1042b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","CTOR"],"gpt_icon":0},{"id":"2514817463","title":"Citius Oncology, Inc.盘中异动 早盘快速下挫5.51%报1.12美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514817463","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514817463?lang=zh_cn&edition=full","pubTime":"2025-02-27 23:27","pubTimestamp":1740670065,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日23时27分,Citius Oncology, Inc.股票出现异动,股价大幅下挫5.51%。截至发稿,该股报1.12美元/股,成交量8002股,换手率0.01%,振幅3.73%。Citius Oncology, Inc.股票所在的制药行业中,整体涨幅为0.99%。Citius Oncology, Inc.公司简介:Citius Oncology Inc 是一家专业制药公司,致力于针对肿瘤产品未满足需求的重症护理产品的开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227232745abdf7d67&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227232745abdf7d67&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CTOR","BK4007","PTPI","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.citiusonc.com","stockEarnings":[{"period":"1week","weight":0.018},{"period":"1month","weight":0.0367},{"period":"3month","weight":-0.1567},{"period":"6month","weight":-0.343},{"period":"1year","weight":-0.0583},{"period":"ytd","weight":0.13}],"compareEarnings":[{"period":"1week","weight":0.0038},{"period":"1month","weight":-0.0028},{"period":"3month","weight":0.0128},{"period":"6month","weight":0.0731},{"period":"1year","weight":0.1443},{"period":"ytd","weight":0.015}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Citius Oncology, Inc.(前身为TenX Keane Acquisition)于2021年3月1日在开曼群岛注册成立,并于2024年8月5日作为特拉华州公司迁移并归化。Citius Oncology将作为一个平台,开发和商业化新型靶向肿瘤疗法。2024年8月,其主要资产LYMPHIR获得FDA批准,用于治疗至少接受过一次全身治疗的复发或难治性CTCL成人患者。","yearOnYearQuotes":[{"month":1,"riseRate":1,"avgChangeRate":0.027634},{"month":2,"riseRate":0.75,"avgChangeRate":0.017896},{"month":3,"riseRate":0.666667,"avgChangeRate":-0.070112},{"month":4,"riseRate":0.666667,"avgChangeRate":-0.017645},{"month":5,"riseRate":1,"avgChangeRate":0.020372},{"month":6,"riseRate":0.666667,"avgChangeRate":1.280036},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.177544},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.282178},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.091201},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.091127},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.146553},{"month":12,"riseRate":0.666667,"avgChangeRate":-0.005673}],"exchange":"NASDAQ","name":"CITIUS ONCOLOGY INC","nameEN":"CITIUS ONCOLOGY INC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"CITIUS ONCOLOGY INC(CTOR)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供CITIUS ONCOLOGY INC(CTOR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"CITIUS ONCOLOGY INC,CTOR,CITIUS ONCOLOGY INC股票,CITIUS ONCOLOGY INC股票老虎,CITIUS ONCOLOGY INC股票老虎国际,CITIUS ONCOLOGY INC行情,CITIUS ONCOLOGY INC股票行情,CITIUS ONCOLOGY INC股价,CITIUS ONCOLOGY INC股市,CITIUS ONCOLOGY INC股票价格,CITIUS ONCOLOGY INC股票交易,CITIUS ONCOLOGY INC股票购买,CITIUS ONCOLOGY INC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"CITIUS ONCOLOGY INC(CTOR)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供CITIUS ONCOLOGY INC(CTOR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}